Day One Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Rhea-AI Summary

Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) successfully closed an upsized public offering of 11,500,000 shares at $15.00 per share on June 17, 2022. This offering, which included an option for underwriters to purchase an additional 1,500,000 shares, generated gross proceeds of $172.5 million. The funds raised will aid Day One in advancing its targeted therapies for pediatric cancer. J.P. Morgan, Cowen, and Piper Sandler managed the offering. The securities are registered under the SEC's regulations, with full details available on their website.

Positive

• Gross proceeds of $172.5 million from the public offering will aid in advancing targeted therapies for pediatric cancer.
• The offering demonstrates strong market confidence, as all shares were offered by Day One.

Negative

• Shareholder dilution may occur as a result of the new shares issued in the public offering.

SOUTH SAN FRANCISCO, Calif., June 21, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the closing on June 17, 2022 of its previously announced upsized underwritten public offering of 11,500,000 shares of its common stock, including the full exercise of the underwriters’ option to purchase 1,500,000 additional shares, at a public offering price of $15.00 per share. All shares of common stock were offered by Day One. The gross proceeds to Day One from the offering, before deducting underwriting discounts and commissions and other offering expenses, were $172.5 million.

J.P. Morgan, Cowen and Piper Sandler acted as the joint book-running managers for the offering. Wedbush PacGrow acted as the lead manager for the offering.

The securities were offered by Day One pursuant to a registration statement on Form S-3 previously filed and declared effective by the Securities and Exchange Commission (SEC). The offering was made only by means of a prospectus and prospectus supplement that form a part of the registration statement. A final prospectus supplement and accompanying base prospectus relating to and describing the terms of the offering have been filed with the SEC and are available on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and accompanying base prospectus may also be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204, or via email at prospectus-eq_fi@jpmchase.com; Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com; or Piper Sandler & Co., 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, Attention: Prospectus Department, by telephone at (800) 747-3924, or by email at prospectus@psc.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company that believes when it comes to pediatric cancer, we can do better. We put kids first and are developing targeted therapies that deliver to their needs. Day One was founded to address a critical unmet need: the dire lack of therapeutic development in pediatric cancer. The Company’s name was inspired by the “The Day One Talk” that physicians have with patients and their families about an initial cancer diagnosis and treatment plan. Day One aims to re-envision cancer drug development and redefine what’s possible for all people living with cancer—regardless of age—starting from Day One.

Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important emerging cancer treatments. The Company’s lead product candidate, tovorafenib (DAY101), is an investigational, oral, brain-penetrant, highly-selective type II pan-RAF kinase inhibitor. The Company’s pipeline also includes pimasertib, an investigational, oral, highly-selective small molecule inhibitor of mitogen‐activated protein kinases 1 and 2 (MEK-1/-2). Day One is based in South San Francisco.

Cautionary Note Regarding Forward‐Looking Statements

This press release contains forward‐looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward‐looking statements reflect the current beliefs and expectations of management and include, but are not limited to, statements regarding the timing, size and expected gross proceeds of the offering, the satisfaction of customary closing conditions related to the offering and sale of securities, and Day One’s ability to complete the offering. All statements other than statements of historical fact are statements that could be deemed forward‐looking statements. Although Day One believes that the expectations reflected in such forward‐looking statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward‐looking statements are subject to risks and uncertainties that may cause Day One’s actual activities or results to differ significantly from those expressed in any forward‐looking statement, including, without limitation, risks and uncertainties related to market conditions and the satisfaction of closing conditions related to the public offering, and the risks and uncertainties described under the heading “Risk Factors” in documents Day One files from time to time with the SEC, including Day One’s Quarterly Report on Form 10‐Q filed with the SEC on May 12, 2022, the preliminary prospectus supplement relating to this offering, and its future periodic reports to be filed with the SEC. These forward‐looking statements speak only as of the date of this press release, and Day One undertakes no obligation to revise or update any forward‐looking statements to reflect events or circumstances after the date hereof.

Contacts:

Media:
1AB
Dan Budwick
dan@1abmedia.com

Investors:
LifeSci Advisors
Hans Vitzthum 
hans@lifesciadvisors.com 

FAQ

What was the size of Day One Biopharmaceuticals' public offering?

The public offering consisted of 11,500,000 shares.

What was the public offering price for shares of DAWN?

The public offering price was $15.00 per share.

What was the total gross proceeds from the offering for DAWN?

The total gross proceeds from the offering were $172.5 million.

When did Day One Biopharmaceuticals close its public offering?

The public offering closed on June 17, 2022.

Who managed the public offering for Day One Biopharmaceuticals?

J.P. Morgan, Cowen, and Piper Sandler acted as the joint book-running managers.